New inhaled drug shows promise for cystic fibrosis in early trial
Disease control
Completed
This study tested an inhaled drug called ETD001 in 57 adults with cystic fibrosis. The trial had two parts: one to check safety over 7 days, and another to see if the drug improves lung function over 28 days. Participants took the drug or a placebo twice daily. The goal is to fin…
Phase: PHASE2 • Sponsor: Enterprise Therapeutics Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC